Foreign Pharmas Seek To Fill Japan Vacuum For Antibody Drugs
This article was originally published in PharmAsia News
The lack of antibody drugs marketed by Japanese drug makers is leading foreign pharmas to put their own versions on the market in Japan. Novartis AG is expected to be the first foreign firm to enter the market by the end of the year, with its Xolair (omalizumab) for treating asthma. Companies expected to follow Novartis to the market soon after include Bristol-Myers Squibb and Merck Serono International with their Erbitux (cerbitux) colon cancer drug. Other firms are holding clinical trials in Japan for drug candidates. (Click here for more - a subscription may be required
You may also be interested in...
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.